中国医学创新
中國醫學創新
중국의학창신
MEDICAL INNOVATION OF CHINA
2014年
21期
1-5,6
,共6页
张伟斌%陈丹%马伟钦%何兴祥%陈羽%王丽京
張偉斌%陳丹%馬偉欽%何興祥%陳羽%王麗京
장위빈%진단%마위흠%하흥상%진우%왕려경
结直肠癌%肝转移%差异蛋白质
結直腸癌%肝轉移%差異蛋白質
결직장암%간전이%차이단백질
Colorectal Carcinoma%Liver Metastasis%Proteomics
目的:利用蛋白质组学技术分离、鉴定结直肠癌有无肝转移患者血清中差异蛋白质,筛选诊断肝转移的血清蛋白标志物。方法:根据入组条件,收集结直肠癌无肝转移病例、有肝转移病例,在两组中随机抽取12例血清样本,同组血清等量混合进行双向凝胶电泳,建立两组血清蛋白质双向电泳图谱,用Image-Master V5.0软件寻找两组差异蛋白质点,MALDI-TOF-MS对差异蛋白质进行鉴定,查询生物信息数据库对差异蛋白质进行初步分析。结果:两组比较差异在2倍以上蛋白质有8种,其中5个蛋白质表达上调,3个蛋白质表达下调;两组每个差异蛋白灰度体平均值比较差异均有统计学意义(P<0.05)。通过数据库搜索鉴定出7种蛋白质,上调的5个蛋白质分别是Transferrin、Complement component C9、RNA directed DNA polymerase(RNA指导的DNA合成酶)、Conserved hypothetical-protein(假定蛋白质)、SEC14L17 kDa protein;下调的2个蛋白质分别是Haptoglobin和Isoform 1 of Serum albumin。结论:结直肠癌有无肝转移患者血清中的蛋白质表达谱有一定的差异性,这些差异蛋白质可能成为诊断肝转移的血清标志物。
目的:利用蛋白質組學技術分離、鑒定結直腸癌有無肝轉移患者血清中差異蛋白質,篩選診斷肝轉移的血清蛋白標誌物。方法:根據入組條件,收集結直腸癌無肝轉移病例、有肝轉移病例,在兩組中隨機抽取12例血清樣本,同組血清等量混閤進行雙嚮凝膠電泳,建立兩組血清蛋白質雙嚮電泳圖譜,用Image-Master V5.0軟件尋找兩組差異蛋白質點,MALDI-TOF-MS對差異蛋白質進行鑒定,查詢生物信息數據庫對差異蛋白質進行初步分析。結果:兩組比較差異在2倍以上蛋白質有8種,其中5箇蛋白質錶達上調,3箇蛋白質錶達下調;兩組每箇差異蛋白灰度體平均值比較差異均有統計學意義(P<0.05)。通過數據庫搜索鑒定齣7種蛋白質,上調的5箇蛋白質分彆是Transferrin、Complement component C9、RNA directed DNA polymerase(RNA指導的DNA閤成酶)、Conserved hypothetical-protein(假定蛋白質)、SEC14L17 kDa protein;下調的2箇蛋白質分彆是Haptoglobin和Isoform 1 of Serum albumin。結論:結直腸癌有無肝轉移患者血清中的蛋白質錶達譜有一定的差異性,這些差異蛋白質可能成為診斷肝轉移的血清標誌物。
목적:이용단백질조학기술분리、감정결직장암유무간전이환자혈청중차이단백질,사선진단간전이적혈청단백표지물。방법:근거입조조건,수집결직장암무간전이병례、유간전이병례,재량조중수궤추취12례혈청양본,동조혈청등량혼합진행쌍향응효전영,건립량조혈청단백질쌍향전영도보,용Image-Master V5.0연건심조량조차이단백질점,MALDI-TOF-MS대차이단백질진행감정,사순생물신식수거고대차이단백질진행초보분석。결과:량조비교차이재2배이상단백질유8충,기중5개단백질표체상조,3개단백질표체하조;량조매개차이단백회도체평균치비교차이균유통계학의의(P<0.05)。통과수거고수색감정출7충단백질,상조적5개단백질분별시Transferrin、Complement component C9、RNA directed DNA polymerase(RNA지도적DNA합성매)、Conserved hypothetical-protein(가정단백질)、SEC14L17 kDa protein;하조적2개단백질분별시Haptoglobin화Isoform 1 of Serum albumin。결론:결직장암유무간전이환자혈청중적단백질표체보유일정적차이성,저사차이단백질가능성위진단간전이적혈청표지물。
To use proteomics separation method identify colorectal carcinoma patients’ serum proteins,so as to differentiate and diagnostic the serum protein biomarkers for liver metastases.Method:According to inclusion criterion,patients had been divided into colorectal cancer patients with liver metastases,and patients without liver metastases. Two groups were be randomized into 12 serum samples,same amount of serum proteins were mixed in each group by two-way clear gel electrophoresis,followed by building two sets of two-dimensional electrophoresis pattern. Image-Master V5.0 software was used to find the differences between two samples. Kam proteins were differentiated by Matrix-assisted laser desorption/ionization time of flight mass spectrometry(MALDI-TOF-MS). The differentiated expressed proteins in given bioinformatics databases was analyzed.Result:The colorectal liver metastases group and the non-colorectal liver metastases group showed that eight proteome were spotted with more than two differentials,of which five proteins were up-regulated and two were down-regulated. Each protein gray body average differences between the two groups had statistical significance(P<0.05). Five up-regulated proteins were:Transferrin,Complement component C9, RNA directed DNA polymerase,Conserved hypothetical-protein,SEC14L1 7 kDa protein;two down-regulated proteins were Haptoglobin and Serum albumin Isoform 1.Conclusion:Serum protein expression spectrum shows differential in colorectal carcinoma patients with liver metastases. This differential may be the diagnostic serum biomarkers for liver metastases.